Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.
You may also be interested in...
Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
Medicare carrier Novitas has proposed to cut reimbursement for long-term electrocardiogram monitoring, which could be a major headache for companies like iRhythm.